Safety of oxaliplatin in the treatment of colorectal cancer
- PMID: 11204657
Safety of oxaliplatin in the treatment of colorectal cancer
Abstract
The new platinum compound oxaliplatin (Eloxatin) appears to have activity, either alone or in combination, as both first- and second-line therapy for advanced colorectal cancer. Unlike other platinum derivatives, it is not associated with significant nephrotoxicity or ototoxicity. The addition of oxaliplatin at 85 mg/m2 to a fluorouracil/leucovorin-based regimen administered every 2 weeks is well tolerated. The incidence of diarrhea and stomatitis increases with the addition of oxaliplatin, but can be managed by adjusting the dose. There is also a significantly higher incidence of grade 3 or 4 neutropenia with oxaliplatin. Neutropenic febrile complications are rare. The occurrence of other hematologic, hepatic, or renal toxicities does not increase when oxaliplatin is added to fluorouracil-based regimens. Unlike other agents used for the treatment of colorectal cancer, oxaliplatin causes acute and chronic neurosensory symptoms. These acute symptoms are managed by taking precautions (e.g., avoid cold drinks/food for a few days following treatment). Cumulative neurotoxicity is the dose-limiting toxicity associated with oxaliplatin treatment. This toxicity appears reversible with discontinuation of the drug and typically occurs well after the onset of tumor response.
Similar articles
-
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.Surg Oncol. 2010 Mar;19(1):38-45. doi: 10.1016/j.suronc.2009.02.015. Epub 2009 Apr 2. Surg Oncol. 2010. PMID: 19345093
-
Efficacy of oxaliplatin in the treatment of colorectal cancer.Oncology (Williston Park). 2000 Dec;14(12 Suppl 11):9-14. Oncology (Williston Park). 2000. PMID: 11204666 Review.
-
Oxaliplatin in colorectal cancer: current studies.Oncology (Williston Park). 2000 Dec;14(12 Suppl 11):42-7. Oncology (Williston Park). 2000. PMID: 11204663 Review.
-
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.J Clin Oncol. 2003 Jul 15;21(14):2703-7. doi: 10.1200/JCO.2003.02.071. J Clin Oncol. 2003. PMID: 12860947 Clinical Trial.
-
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.Clin Colorectal Cancer. 2003 Aug;3(2):108-12. doi: 10.3816/CCC.2003.n.017. Clin Colorectal Cancer. 2003. PMID: 12952567 Clinical Trial.
Cited by
-
Transplanted kidney loss during colorectal cancer chemotherapy: A case report.World J Clin Cases. 2022 Jul 6;10(19):6647-6655. doi: 10.12998/wjcc.v10.i19.6647. World J Clin Cases. 2022. PMID: 35979324 Free PMC article.
-
Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer.Oncotarget. 2018 Jan 9;9(8):7902-7917. doi: 10.18632/oncotarget.24083. eCollection 2018 Jan 30. Oncotarget. 2018. PMID: 29487701 Free PMC article.
-
Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.J Pain. 2009 May;10(5):534-41. doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23. J Pain. 2009. PMID: 19231296 Free PMC article.
-
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.Front Nephrol. 2024 Aug 9;4:1436896. doi: 10.3389/fneph.2024.1436896. eCollection 2024. Front Nephrol. 2024. PMID: 39185276 Free PMC article. Review.
-
Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.Drugs. 2003;63(19):2127-56. doi: 10.2165/00003495-200363190-00013. Drugs. 2003. PMID: 12962525 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
